Search research articles
Contact Us
Filters
Showing results (41-50 of 224) with videos related to
Page
of 23
Sort By:
Current Opinion in Pharmacology
|
August 29, 2021
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities
Ziyan Pan, Jian-Gao Fan, Mohammed Eslam
Gastroenterology
|
February 12, 2020
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J Sanyal, Jacob George, et al.
Hepatobiliary Surgery and Nutrition
|
January 10, 2022
The role of B cells in metabolic (dysfunction)-associated fatty liver disease
Ziyan Pan, Wah-Kheong Chan, Mohammed Eslam
Alimentary Pharmacology & Therapeutics
|
September 25, 2018
Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection. Authors' reply
Rasha El Sharkawy, Jacob George, Mohammed Eslam
Hepatology International
|
April 17, 2023
MAFLD and chronic kidney disease: two sides of the same coin?
Ziyan Pan, Saleh A Alqahtani, Mohammed Eslam
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 4, 2026
Assessment of MAFLD/MASLD Classification Using the Updated Lancet Obesity Definition
Alaa M Mostafa, Yasser Fouad, Mohammed Eslam
Gut
|
January 22, 2011
Insulin resistance and hepatitis C: an evolving story
Mohammed Eslam, Mahmoud Aboelneen Khattab, Stephen A Harrison
World Journal of Gastroenterology
|
May 12, 2020
Macrophages in metabolic associated fatty liver disease
Jawaher Alharthi, Olivier Latchoumanin, Jacob George, et al.
Trends in Genetics : TIG
|
May 13, 2020
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
Ali Bayoumi, Henning Grønbæk, Jacob George, et al.
Hormones (Athens, Greece)
|
August 3, 2022
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Page
of 23
Search research articles
Search
Showing results (41-50 of 224) with videos related to
Sort By:
Page
of 23
Current Opinion in Pharmacology
|
August 29, 2021
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities
Ziyan Pan, Jian-Gao Fan, Mohammed Eslam
Gastroenterology
|
February 12, 2020
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J Sanyal, Jacob George, et al.
Hepatobiliary Surgery and Nutrition
|
January 10, 2022
The role of B cells in metabolic (dysfunction)-associated fatty liver disease
Ziyan Pan, Wah-Kheong Chan, Mohammed Eslam
Alimentary Pharmacology & Therapeutics
|
September 25, 2018
Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection. Authors' reply
Rasha El Sharkawy, Jacob George, Mohammed Eslam
Hepatology International
|
April 17, 2023
MAFLD and chronic kidney disease: two sides of the same coin?
Ziyan Pan, Saleh A Alqahtani, Mohammed Eslam
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 4, 2026
Assessment of MAFLD/MASLD Classification Using the Updated Lancet Obesity Definition
Alaa M Mostafa, Yasser Fouad, Mohammed Eslam
Gut
|
January 22, 2011
Insulin resistance and hepatitis C: an evolving story
Mohammed Eslam, Mahmoud Aboelneen Khattab, Stephen A Harrison
World Journal of Gastroenterology
|
May 12, 2020
Macrophages in metabolic associated fatty liver disease
Jawaher Alharthi, Olivier Latchoumanin, Jacob George, et al.
Trends in Genetics : TIG
|
May 13, 2020
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
Ali Bayoumi, Henning Grønbæk, Jacob George, et al.
Hormones (Athens, Greece)
|
August 3, 2022
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Page
of 23